Literature DB >> 9688277

The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate.

U Nuber1, S E Schwarz, M Scheffner.   

Abstract

Recognition of substrate proteins by the ubiquitin-conjugation system is a highly specific and regulated event and involves the action of ubiquitin-conjugating enzymes (E2) and ubiquitin-protein ligases (E3). However, the E2 and E3 involved in the recognition of particular substrates have been identified in only a few cases. The ubiquitin-protein ligase E6-associated protein (E6-AP) was originally identified as a protein involved in the human papillomavirus E6-oncoprotein-induced degradation of p53. The substrate proteins of E6-AP in the absence of the E6 oncoprotein, however, have not been identified. We show here that E6-AP can target itself for ubiquitination in vitro and provide evidence that, under conditions of overexpression, E6-AP efficiently promotes its own degradation in vivo. Autoubiquitination of E6-AP is mediated mainly by intermolecular transfer of ubiquitin. In addition, highly ubiquitinated forms of E6-AP cannot bind to p53 in the presence of the E6 oncoprotein and, conversely, binding of E6-AP to p53 interferes with ubiquitination of E6-AP. These results suggest that autoubiquitination and subsequent degradation of E6-AP represents a mechanism to control intracellular E6-AP levels by inactivating E6-AP molecules that are not bound to substrate proteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688277     DOI: 10.1046/j.1432-1327.1998.2540643.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  46 in total

1.  In vivo action of the HRD ubiquitin ligase complex: mechanisms of endoplasmic reticulum quality control and sterol regulation.

Authors:  R G Gardner; A G Shearer; R Y Hampton
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

2.  Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome.

Authors:  Richard M Gustin; Terry Jo Bichell; Michael Bubser; Jennifer Daily; Irina Filonova; Davit Mrelashvili; Ariel Y Deutch; Roger J Colbran; Edwin J Weeber; Kevin F Haas
Journal:  Neurobiol Dis       Date:  2010-04-25       Impact factor: 5.996

3.  Ubiquitin over-expression promotes E6AP autodegradation and reactivation of the p53/MDM2 pathway in HeLa cells.

Authors:  Rita Crinelli; Marzia Bianchi; Michele Menotta; Elisa Carloni; Elisa Giacomini; Marzia Pennati; Mauro Magnani
Journal:  Mol Cell Biochem       Date:  2008-07-09       Impact factor: 3.396

4.  Novel control of S phase of the cell cycle by ubiquitin-conjugating enzyme H7.

Authors:  Elizabeth A Whitcomb; Edward J Dudek; Qing Liu; Allen Taylor
Journal:  Mol Biol Cell       Date:  2008-10-22       Impact factor: 4.138

Review 5.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

6.  Physical and functional interaction of the HECT ubiquitin-protein ligases E6AP and HERC2.

Authors:  Simone Kühnle; Ulrike Kogel; Sandra Glockzin; Andreas Marquardt; Aaron Ciechanover; Konstantin Matentzoglu; Martin Scheffner
Journal:  J Biol Chem       Date:  2011-04-14       Impact factor: 5.157

Review 7.  Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms.

Authors:  P de Bie; A Ciechanover
Journal:  Cell Death Differ       Date:  2011-03-04       Impact factor: 15.828

Review 8.  Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease.

Authors:  Ashok N Hegde; Sudarshan C Upadhya
Journal:  Biochim Biophys Acta       Date:  2010-08-03

9.  E6AP in the brain: one protein, dual function, multiple diseases.

Authors:  Jimmy El Hokayem; Zafar Nawaz
Journal:  Mol Neurobiol       Date:  2013-10-05       Impact factor: 5.590

10.  Ubiquitin control of S phase: a new role for the ubiquitin conjugating enzyme, UbcH7.

Authors:  Elizabeth A Whitcomb; Allen Taylor
Journal:  Cell Div       Date:  2009-08-07       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.